BD PartnerPath™ Program

De-risking with accelerated BD PartnerPath™ Program Delivery

Combination product development is inherently challenging. Let's face those challenges together!

From acquiring data and selecting the ideal drug delivery system, to formulating your regulatory strategy and conducting clinical trials, the road to commercialization can be fraught with challenges.

These unexpected challenges can delay your launch, increase costs, negatively impact profitability[1] and impact the viability of your project.

BD PartnerPath™ Program supports the development of combination products, with quick access to small quantities of preconfigured drug delivery systems and supporting documentation.

Get technical support and solutions across the combination product development journey.

Get quick access to small quantities of preconfigured BD drug delivery systems - delivery within 2 weeks*

- Device identification[2,3]
- Drug compatibility[4]
- Operational, performance and integration feasibility[1]
- Regulatory registration[5,6,7]

Leverage the BD PartnerPath™ Program and BD expertise

- Strategize on development processes
- Develop a regulatory strategy
- Conduct human factor studies
- Utilize research and development data**
- Get documentation to underpin your product development

Focus your resources on your core expertise

Support in a competitive market, whatever your drug development experience.

* of BD confirmation of your order
** Data currently available for selected systems

1. Source: "Challenges with System Integration" [external study], Franklin Lakes, NJ, USA: GLG 2019 Double blinded qualitative market research with 8 industry experts. Participants worked directly on drug development projects, requiring combination devices (primary and secondary containers) and included the assembly of PFS and/or PFS with autoinjectors. **2.** Hopkins BP, Miller KJ. Swimming upstream: developing and commercializing diabetes products in a patent protected world. J Diabetes Sci Technol. 2013;7(2):302- 307. Published 2013 Mar 1. doi:10.1177/193229681300700203. **3.** van den Bemt BJF, Gettings L, Domańska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384- 392. doi:10.1080/10717544.2019.1587043. **4.** Zhaoyang Li & Rachael Easton (2018) Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics, mAbs, 10:1, 18-33, DOI: 10.1080/19420862.2017.1392424. **5.** Pourkavoos, N. Unique Risks, Benefits, and Challenges of Developing Drug-Drug Combination Products in a Pharmaceutical Industrial Setting. comb.prod.ther. 2, 2 (2012). https://doi.org/10.1007/s13556-012-0002-2. **6.** ISO11608 requirements for needle injection systems. https://www.iso.org/obp/ui/#iso:std:iso:11608:-1:ed-3:v1:en. **7.** Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469- 478.

Let's have a conversation!

BD Medical Pharmaceutical Systems: 1 Becton Drive, Franklin Lakes, NJ 07417, +1 800 225 3310

bd.com